Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
06 2019
Historique:
received: 16 05 2018
accepted: 24 01 2019
pubmed: 5 3 2019
medline: 18 12 2019
entrez: 5 3 2019
Statut: ppublish

Résumé

There are regional differences in the patient characteristics, management, and outcomes of hospitalized patients with heart failure (HF). The aim of this study was to evaluate the clinical characteristics and outcomes of Japanese patients who are hospitalized with HF on the basis of the left ventricular ejection fraction (LVEF) stratum. We retrospectively conducted a multicentre cohort study of 1245 hospitalized patients with decompensated HF between 2013 and 2014. Of these patients, 36% had an LVEF < 40% [HF with reduced ejection fraction (HFrEF), median age 72 years, 71% male], 21% had an LVEF 40-49% [HF with mid-range EF (HFmrEF), 77 years, 56% male], and 43% had an LVEF ≥ 50% [HF with preserved EF (HFpEF), 81 years, 44% male]. The primary outcome was death from any cause, and the secondary outcomes were cardiac death and re-hospitalization due to worsened HF after hospital discharge. There were high proportions of non-ischaemic cardiomyopathy (32%) in HFrEF patients, coronary artery disease (44%) in HFmrEF patients, and valvular disease (39%) in HFpEF patients. The frequencies of intravenous diuretic and natriuretic peptide administration during hospitalization were 66% and 30%, respectively. The median hospital stay for the overall population was 19 days, and the length of stay was >7 days for >90% of patients. In-hospital mortality was 7%, but was not different among the LVEF groups (HFrEF 7%, HFmrEF 6%, and HFpEF 8%). After a median follow-up of 19 months (range, 3-26 months), 192 (17%) of the 1156 patients who were discharged alive died, and 534 (46%) were re-hospitalized after hospital discharge. There were no significant differences in mortality after hospital discharge among the three LVEF groups (HFrEF 18%, HFmrEF 16%, and HFpEF 16%). There were no differences in cardiac death or re-hospitalization due to worsened HF after hospital discharge among the LVEF groups (cardiac death: HFrEF 8%, HFmrEF 7%, and HFpEF 7%; re-hospitalization due to worsened HF: HFrEF 19%, HFmrEF 16%, and HFpEF 17%). Multivariable-adjusted analyses showed that the HFmrEF and HFrEF groups, compared with the HFpEF group, were not associated with an increased risk for in-hospital death or death after hospital discharge. Non-cardiac causes of death and re-hospitalization after hospital discharge accounted for 35% and 38%, respectively. Our results revealed different clinical characteristics but similar mortality rates in the HFrEF, HFmrEF, and HFpEF groups. The most common cause of death and re-hospitalization after hospital discharge was HF, but non-cardiac causes also contributed to their prognosis. Integrated management approaches will be required for HF patients.

Identifiants

pubmed: 30829002
doi: 10.1002/ehf2.12418
pmc: PMC6487690
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

475-486

Informations de copyright

© 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

J Am Coll Cardiol. 2013 Apr 9;61(14):1498-506
pubmed: 23500300
J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8
pubmed: 18992654
Am J Cardiol. 2018 Mar 15;121(6):731-738
pubmed: 29394996
Eur Heart J. 2014 Apr;35(16):1022-32
pubmed: 24618346
J Clin Epidemiol. 2014 Sep;67(9):1035-43
pubmed: 24837298
Eur Heart J. 2001 Jan;22(2):153-64
pubmed: 11161917
JACC Heart Fail. 2016 Jun;4(6):464-72
pubmed: 27256749
Circ J. 2013;77(9):2209-17
pubmed: 23955345
Am Heart J. 2010 Jun;159(6):949-955.e1
pubmed: 20569705
ESC Heart Fail. 2019 Jun;6(3):475-486
pubmed: 30829002
Circulation. 2009 May 26;119(20):2663-70
pubmed: 19433755
Circ J. 2009 Oct;73(10):1893-900
pubmed: 19644216
Eur J Prev Cardiol. 2017 Dec;24(18):1979-1987
pubmed: 29086584
J Cardiol. 2013 Aug;62(2):95-101
pubmed: 23672787
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
Eur Heart J. 2006 Nov;27(22):2725-36
pubmed: 17000631
Eur J Heart Fail. 2017 Oct;19(10):1258-1269
pubmed: 28370829
Qual Life Res. 2005 Feb;14(1):107-18
pubmed: 15789945
Int J Cardiol. 2017 Aug 15;241:243-248
pubmed: 28476514
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur Heart J. 2012 Jul;33(14):1750-7
pubmed: 21821849
JACC Heart Fail. 2017 Nov;5(11):763-771
pubmed: 29032140
Circ J. 2011;75(4):823-33
pubmed: 21436596
Circ Res. 2013 Aug 30;113(6):646-59
pubmed: 23989710
Heart Vessels. 2018 Sep;33(9):997-1007
pubmed: 29569034
Eur J Intern Med. 2018 May;51:1-10
pubmed: 29482882
JAMA. 2006 Nov 8;296(18):2217-26
pubmed: 17090768
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
Nihon Rinsho. 2003 May;61(5):709-14
pubmed: 12754992
Crit Care Med. 2013 Jan;41(1):9-14
pubmed: 23232287
Circ J. 2008 Mar;72(3):489-91
pubmed: 18296852
Eur Heart J. 2015 Nov 1;36(41):2793-2867
pubmed: 26320108
Eur J Heart Fail. 2015 Sep;17(9):884-92
pubmed: 26222508
Circ Heart Fail. 2013 Mar;6(2):279-86
pubmed: 23271790
Heart. 2009 Mar;95(3):216-20
pubmed: 18728065
Circulation. 2009 Jun 23;119(24):3070-7
pubmed: 19506115
Eur J Heart Fail. 2013 Jul;15(7):808-17
pubmed: 23537547
Circ J. 2008 Dec;72(12):2015-20
pubmed: 18931450
Stroke. 2004 Feb;35(2):607-12
pubmed: 14726549

Auteurs

Tsuyoshi Shiga (T)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Atsushi Suzuki (A)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Shoji Haruta (S)

Department of Cardiology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan.

Fumiaki Mori (F)

Department of Cardiology, National Yokohama Medical Center, Yokohama, Japan.

Yoshimi Ota (Y)

Department of Cardiology, Saiseikai Kurihashi Hospital, Kuki, Japan.

Masahiro Yagi (M)

Department of Cardiology, Cardiovascular Center of Sendai, Sendai, Japan.

Toshiaki Oka (T)

Department of Cardiology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

Hiroyuki Tanaka (H)

Department of Cardiology, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.

Satoshi Murasaki (S)

Department of Cardiology, Tama-Hokubu Medical Center, Higashimurayama, Japan.

Takao Yamauchi (T)

Department of Cardiology, JCHO Sagamino Hospital, Sagamihara, Japan.

Joji Katoh (J)

Department of Cardiology, Shinmatsudo Central General Hospital, Matsudo, Japan.

Hidetoshi Hattori (H)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Noriko Kikuchi (N)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Erisa Watanabe (E)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Yuichiro Yamada (Y)

Department of Cardiology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan.

Shintaro Haruki (S)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Tomohito Kogure (T)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Tsuyoshi Suzuki (T)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Department of Cardiology and Pneumology, University Medical Center Göttingen and DZHK (German Center for Cardiovascular Research), Göttingen, Germany.

Yoshio Uetsuka (Y)

Institute of Geriatrics, Tokyo Women's Medical University, Tokyo, Japan.

Nobuhisa Hagiwara (N)

Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH